Extend due date to 2/2/2026.

This is an unrestricted procurement for Ustekinumab Pen/Syringes or Biosimilars to supply multiple federal health agencies. The contract period is for one base year plus four pre-priced one-year option periods. The estimated annual usage is detailed for three specific item descriptions, totaling over 58,000 syringes/vials. Products will be distributed through the VA and DOD Pharmaceutical Prime Vendor programs, and offerors must supply products under their own unique label and NDC number. Biosimilar products must be FDA-licensed and listed in the FDA Purple Book.